Journalistic or editorial piece covering the new generation of obesity medications entering the pipeline—including retatrutide alongside semaglutide and tirzepatide. Discusses how these drugs are transforming the obesity treatment landscape, challenges of access and cost, and what further innovation may follow. Provides commentary on the paradigm shift toward pharmacological obesity management.
Seetharaman, Rajmohan; Pandit, Swarnima